A Potential Drug Target or Biomarker for GSEC (DCPS-AS1) (G399972)

Target Name: GSEC

NCBI ID: G399972

GSEC

Other Name(s): DCPS-AS1 | ST3GAL4-AS1 | G-quadruplex forming sequence containing lncRNA

A Potential Drug Target or Biomarker for GSEC (DCPS-AS1)

Introduction

Gastrin-secretory cell-derived peptide (GSEC) is a protein that plays a crucial role in the regulation of gastric acid secretion in the stomach. Mutations in the GSEC gene have been associated with various gastrointestinal disorders, including gastroesophageal reflux disease (GERD), heartburn (EPI), and stomach cancer. The discovery of new drug targets or biomarkers for GSEC has the potential to improve treatment options for these conditions. In this article, we will explore the potential drug target or biomarker of GSEC, focusing on the gene symbol DCPS-AS1.

GSEC: Structure and Function

GSEC is a 21-kDa protein that is synthesized in the stomach lining cells. It is composed of a pre-secretory stage region (PSR), a transmembrane region (TMR), and an intracellular domain (ICD). The PSR region contains the catalytic active site for the secretion of gastrin, which is a hormone that stimulates the production of stomach acid. The TMR region is responsible for the delivery of the encoded peptide to the cytosol.

The ICD region is involved in the formation of integrated complexes, which is essential for the stability and processing of the peptide. Mutations in the ICD region have been implicated in the development of various gastrointestinal disorders, including GSEC-related diseases ( 5).

DCPS-AS1: A Potential Drug Target

DCPS-AS1 is a gene that encodes for a protein with similar sequence to the ICD region of GSEC. Mutations in the DCPS-AS1 gene have been observed in individuals with GSEC-related disorders, suggesting that it may be a drug potential target.

The encoded peptide of DCPS-AS1 contains a unique amino acid sequence that is different from that of GSEC. The DCPS-AS1 peptide has a longer carboxy-terminal region and a modified amino acid residue at its C-terminus compared to GSEC. The modified Residue is important for the stability and processing of the peptide.

Furthermore, overexpression of the DCPS-AS1 gene has been shown to increase the levels of GSEC in the stomach lining cells, which may contribute to its potential as a drug target.

DCPS-AS1 Mutation and GSEC-Related Diseases

Mutations in the DCPS-AS1 gene have been observed in individuals with various GSEC-related disorders, including gastroesophageal reflux disease (GERD), heartburn (EPI), and stomach cancer. These mutations have been associated with decreased levels of GSEC and increased production of stomach acid, leading to the development of symptoms such as heartburn, chest pain, and malignancies.

DCPS-AS1 mutations have also been shown to affect the processing and stability of GSEC, leading to changes in its function. Overexpression of the DCPS-AS1 gene has been shown to increase the production of GSEC and enhance its secretion. These findings suggest that DCPS-AS1 may play a crucial role in the development and progression of GSEC-related diseases.

Conclusion

In conclusion, DCPS-AS1 is a gene that encodes for a protein with potential as a drug target or biomarker for GSEC-related disorders. Its unique amino acid sequence and its role in the regulation of GSEC production make it an attractive target for further study . Further research is needed to determine the exact mechanism by which DCPS-AS1 promotes GSEC production and its potential as a drug.

Protein Name: G-quadruplex Forming Sequence Containing LncRNA

The "GSEC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSEC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets